Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $83

Guggenheim analyst Subbu Nambi has reiterated a Buy rating on GeneDx Holdings (NASDAQ: WGS) and increased the price target from $74 to $83. This adjustment reflects a positive outlook for the company in the market.